IN8bio Inc (NASDAQ: INAB) has seen a rise in its stock price by 2.18 in relation to its previous close of 0.17. However, the company has experienced a -8.29% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-29 that NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences. “The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bio’s gamma-delta T cell platform,” said William Ho, CEO and co-founder, IN8bio.
Is It Worth Investing in IN8bio Inc (NASDAQ: INAB) Right Now?
Company’s 36-month beta value is 0.23.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INAB is 64.72M, and currently, short sellers hold a 0.74% ratio of that floaft. The average trading volume of INAB on May 02, 2025 was 5.33M shares.
INAB’s Market Performance
INAB’s stock has seen a -8.29% decrease for the week, with a 1.76% rise in the past month and a -32.13% fall in the past quarter. The volatility ratio for the week is 7.56%, and the volatility levels for the past 30 days are at 9.58% for IN8bio Inc The simple moving average for the past 20 days is 5.15% for INAB’s stock, with a -48.91% simple moving average for the past 200 days.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at -15.37% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.02% of loss for the given period.
Volatility was left at 9.58%, however, over the last 30 days, the volatility rate increased by 7.56%, as shares surge +7.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.51% lower at present.
During the last 5 trading sessions, INAB fell by -8.61%, which changed the moving average for the period of 200-days by -79.88% in comparison to the 20-day moving average, which settled at $0.1651. In addition, IN8bio Inc saw -32.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INAB
The total capital return value is set at -1.7. Equity return is now at value -154.44, with -109.30 for asset returns.
Based on IN8bio Inc (INAB), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.8.
Currently, EBITDA for the company is -27.78 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.08.
Conclusion
In a nutshell, IN8bio Inc (INAB) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
